pbi-shRN K-ras LP

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namepbi-shRN K-ras LP
Drug Alias Namepbi-shRN K-ras LipoplexAnti-k-ras shRNA (Gradalis)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGradalis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGradalis Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A